Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$48.67+0.35%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · RIGL
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 276.8 | 294.3 | 179.3 | 116.9 | 120.2 | 149.2 | 108.6 | 59.3 | 44.5 | — | — | — | — | — | — | — |
| Cost of Revenues | 23.8 | 19.6 | 18.6 | 7.1 | 1.7 | 1.1 | 0.9 | 0.9 | 0.3 | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 122.2 | 115.9 | 113.1 | 105.7 | 112.5 | 91.9 | 76.6 | 74.6 | 70.0 | — | — | — | — | — | — | — |
| R&D Expenses | — | 33.3 | — | 24.5 | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Income | 87.1 | 125.5 | 24.2 | (20.5) | (55.6) | (12.5) | (29.0) | (69.1) | (72.7) | (79.6) | (69.7) | (51.7) | (91.2) | (89.5) | (99.4) | (86.4) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | 7.3 | 7.9 | 6.9 | 3.7 | 4.9 | 1.4 | 0.3 | — | — | — | — | — | 0.0 | 0.0 | 0.0 |
| Interest & Investment Income | 4.3 | 3.7 | 2.1 | 2.3 | 0.7 | 0.0 | 0.6 | 2.5 | 2.2 | 0.9 | 0.4 | 0.2 | 0.2 | 0.4 | 0.5 | 0.4 |
| Net Interest Expenses | — | — | — | 4.6 | 3.0 | 4.8 | 0.8 | (2.2) | — | — | — | — | — | (0.4) | (0.5) | (0.4) |
| EBT, Incl. Unusual Items | 85.6 | 121.8 | 18.4 | (25.1) | (58.6) | (17.3) | (29.7) | — | — | — | — | — | — | — | — | (86.0) |
| Income Tax Expense | (236.3) | (245.2) | 0.9 | 0.0 | — | 0.6 | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
| Net Income | ||||||||||||||||
| Net Income | 321.9 | 367.0 | 17.5 | (25.1) | (58.6) | (17.9) | (29.7) | (66.9) | (70.5) | (78.0) | (69.2) | (51.5) | (90.9) | (89.0) | (98.8) | (86.0) |
| Per Share | ||||||||||||||||
| Basic EPS | 17.36 | 20.40 | 0.99 | (1.44) | (3.44) | (0.11) | (0.18) | — | — | — | — | — | — | — | (1.32) | (1.36) |
| Diluted EPS | 16.45 | 19.48 | 0.99 | (1.44) | (3.44) | (0.11) | (0.18) | — | — | — | — | — | — | — | (1.32) | (1.36) |
| Revenue per Share | 14.14 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 18.5 | 18.0 | 17.6 | 17.4 | 17.0 | 170.5 | 168.8 | — | — | — | — | — | 87.7 | 87.3 | 75.0 | 63.3 |
| Diluted Weighted Avg Shares | 19.6 | 18.8 | 17.7 | 17.4 | 17.0 | 170.5 | 168.8 | — | — | — | — | — | 87.7 | 87.3 | 75.0 | 63.3 |
| Supplemental | ||||||||||||||||
| EBITDA | — | 127.9 | 26.4 | (19.3) | (54.6) | (11.3) | (28.3) | (68.4) | (72.1) | (79.2) | (68.8) | (50.3) | (88.9) | (86.9) | (96.9) | (84.4) |
| EBIT | 87.1 | 125.5 | 24.2 | (20.5) | (55.6) | (12.5) | (29.0) | (69.1) | (72.7) | (79.6) | (69.7) | (51.7) | (91.2) | (89.5) | (99.4) | (86.4) |
| Effective Tax Rate | -276.2% | — | — | 0.0% | — | -3.5% | — | — | — | — | — | — | — | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.